查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1182351

注意力不足過動症的全球市場預測(～2028年) - 藥物，心理治療，教育/訓練，各流通管道，各地區的分析

Attention Deficit Hyperactivity Disorder Market Forecasts to 2028 - Global Analysis By medication, By Psychotherapy, By Education Or Training, Distribution Channel and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

全球注意力不足過動症的市場規模預測將從2022年的132億1,000萬美元，在預測期間內以6.2％的年複合成長率增長，到2028年成長到189億5,000萬美元。

本報告提供全球注意力不足過動症市場調查，提供市場概要，市場規模和預測，趨勢，促進因素·阻礙因素，藥物·心理治療·教育/訓練·各流通管道·各地區的分析等全面性資訊。

目錄

第1章 摘要整理

第2章 序文

第3章 市場趨勢分析

  • 促進因素
  • 阻礙因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19影響

第4章 波特的五力分析

第5章 全球注意力不足過動症市場:藥物

  • 刺激劑
    • 苯丙胺
    • 哌醋甲酯
    • 哌醋甲酯
    • 哌醋甲酯
    • Lisdexamfetamine 二甲磺酸鹽
  • 非刺激劑
    • Atomoxetine
    • Guanfacine
    • Atomoxetine
    • Clonidine
  • 其他的藥物

第6章 全球注意力不足過動症市場:心理治療

  • 行動療法
  • 認知行為治療
  • 家族療法
  • 對人心理治療
  • 其他的心理治療

第7章 全球注意力不足過動症市場:教育/訓練

  • 社會性技術訓練
  • 監護人管理訓練
  • 學校為基礎的干預
  • 其他的教育/訓練

第8章 全球注意力不足過動症市場:各流通管道

  • 零售藥局
  • 醫院藥局
  • 專門診所
  • 電子商務
  • 其他的流通管道

第9章 全球注意力不足過動症市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他的亞太地區
  • 南美
    • 阿根廷
    • 巴西
    • 智利
    • 其他的南美
  • 中東·非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他的中東·非洲

第10章 主要發展

  • 契約，夥伴關係，合作，合資企業
  • 收購與合併
  • 新產品的銷售
  • 擴大
  • 其他的主要策略

第11章 企業簡介

  • Noven Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Neos Therapeutics, Inc.
  • Supernus Pharmaceuticals
  • Novartis AG
  • Johnson & Johnson
  • Lilly, Pfizer Inc.
  • Alcobra Ltd.
  • Neurosigma, Inc
  • Hisamitsu Pharmaceutical Co.,Inc
  • KemPharm, Inc.
  • Curemark, LLC.
  • Mallinckrodt, UCB S.A.
  • Purdue Pharma L.P.
  • Actavis
Product Code: SMRC22169

According to Stratistics MRC, the Global Attention Deficit Hyperactivity Disorder Market is accounted for $13.21 billion in 2022 and is expected to reach $18.95 billion by 2028 growing at a CAGR of 6.2% during the forecast period. Attention Deficit Hyperactivity Disorder is a chronic condition including attention difficulty, hyperactivity and impulsiveness. Attention deficit hyperactivity disorder often begins in childhood and can persist into adulthood. It may contribute to low self-esteem, troubled relationships and difficulty at school or work. Symptoms include limited attention and hyperactivity. There are many treatment options that works best can depend on the individual child and family.

According to the Centers for Diseases Control and Prevention, in September 2021, 8.8% of people have been diagnosed with attention deficit hyperactivity disorder at some point in their lives. Moreover, 13.6 million visits to doctors' offices were made with attention deficit disorder as the primary diagnosis. In addition, increasing spending on the treatment of attention deficit hyperactivity disorder in the United States with rising prescription rates is expected to boost the market.

Market Dynamics:

Driver:

Rise in the incidence of attention deficit hyperactivity disorder

The causes of attention deficit hyperactivity disorder are still unclear, although genetic presence is observed in many cases. The incidence of this disorder is rising at a higher rate, which drives the global attention deficit hyperactivity disorder therapeutics market, as there is no treatment for this disorder. Moreover, increasing attentiveness regarding the syndrome among physicians and patients and opinion-based due to the lack of regular diagnostic tests and, increasing advancements in the medical field, a growing number of researches in neurosciences, and raising awareness about mental illness among people are encouraging the market growth to a significant level.

Restraint:

Involving side effects

Attention deficit hyperactivity disorder medication has side effects such as loss of appetite and trouble sleeping. Other attention deficit hyperactivity disorder medicine side effects include nervousness, irritability, moodiness, headaches, stomachaches, fast heart rate, and high blood pressure. Side effects usually happen in the first few days of starting a new medicine or taking a higher dose these side effects can also be controlled by reducing the dose or changing the medication, due to which patients are not convinced in adopting to the medication treatment thus hindering the market growth.

Opportunity:

Increasing prevalence of attention deficit hyperactivity disorder

Even though the prevalence of the attention deficit hyperactivity disorder is not known this disorder is highly prevalent in many children all around the world, hence there is a major need for the advancement in the medical field and innovated products for the treatment of attention deficit hyperactivity disorder in the market moreover the growth in responsiveness about mental illness amongst people are the factors expected to boost the growth of the attention-deficit hyperactivity disorder market in the forecast period.

Threat:

High cost of medication

The high cost of attention deficit hyperactivity disorder medications, improper reimbursement policies, and side effects related to the medications such as insomnia, anorexia, dizziness, headaches, and mood changes are restraining the growth of the global attention deficit hyperactivity disorder therapeutics market. Moreover, all the side effects connected with the drugs affect the patients lives and hamper the revenue growth of the attention-deficit hyperactivity disorder therapeutics market in the given forecast period.

COVID-19 Impact

The Pandemic has had a lot of harmful impacts on people suffering from attention-deficit hyperactivity disorder. The major reason for the consequence is susceptibility, to the distress caused by the pandemic and physical distancing measures, owing to these factors, the patient can display increased behavioural problems. The increase in the issues will boost the sale of attention deficit hyperactivity disorder therapeutics, and the buying by consumers has finished the stock of the current batch of medicines and forced them to make a fresh batch. Moreover, hospital visits for non-essential medical conditions have been delayed, causing persons with attention deficit hyperactivity disorder to depend totally on drugs helping in boosting the market growth.

The Stimulant segment is expected to be the largest during the forecast period

The Stimulant segment is estimated to have a lucrative growth, due to its increased activity in the brain particularly in areas that play a part in controlling attention and behaviour. Various drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, etc are used in the treatment of Attention Deficit Hyperactivity Disorder. Amphetamines and methylphenidate are common stimulant medications prescribed to children, adolescents, and adults with attention deficit hyperactivity disorder. They work quickly, and there is also a reduction in overall impulsivity and attention deficit hyperactivity disorder symptoms in two hours. The stimulants are the most effective treatment for attention deficit hyperactivity disorder patients to keep them calm and focused. Thus the effectiveness of the stimulant drug in the management of attention deficit hyperactivity disorder boosts the segment growth over the forecast period.

The Behaviour therapy segment is expected to have the highest CAGR during the forecast period

The Behaviour therapy segment is anticipated to witness the fastest CAGR growth during the forecast period, due to effective treatment for attention deficit hyperactivity disorder that can improve a child's behaviour, self-control, and self-esteem. It is most helpful in young children when it is delivered by parents and is a short-term, goal-oriented form of psychotherapy that aims to change negative patterns of thinking and reframe the way a patient feels about herself and her symptoms of attention deficit hyperactivity disorder. Additionally, children benefit in the long term as they can apply the techniques any time they need to handle with negative emotions. Hence all the above factors contribute in the market growth.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the displeased needs and large patient population, and even the ease of access of lower-cost drugs for attention deficit hyperactivity disorder treatment. In addition, factors such as high awareness among healthcare professionals about drugs available for treatment and the rise in disease prevalence, private organizations and the bigger funding from the population are responsible for the regional market's growth. Also, the accessibility of new treatments and technology affects the growing demand and encourages the growth of the regional attention deficit hyperactivity disorder therapeutics market.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the growing alertness about the mental health and the increasing of the incidences of attention-deficit or hyperactivity disorder. Moreover, due to the large number of drug prescriptions, written each year, the increased number of product launches, and the increased collaboration among players to improve market penetration and product development. Furthermore, the high ingestion of additives and preservatives, and the improvising of the coverage for treatment of the condition which in turn are anticipated to further propel the growth of the attention-deficit hyperactivity market in the region in the coming years.

Key players in the market

Some of the key players profiled in the Attention Deficit Hyperactivity Disorder Market include Noven Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Neos Therapeutics, Inc., Supernus Pharmaceuticals, Novartis AG, Johnson & Johnson, Lilly, Pfizer Inc., Alcobra Ltd., Neurosigma, Inc, Hisamitsu Pharmaceutical Co.,Inc , KemPharm, Inc., Curemark, LLC., Mallinckrodt, UCB S.A, Purdue Pharma L.P. Actavis.

Key Developments:

In Nov 2022, Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria. This novel combination also contains an optimized formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration. As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination.

In Oct 2022, Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy. Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of Europe, Canada, Australia and China, a Phase 2b investigational therapy for the treatment of celiac disease.

In Jun 2022, Novartis announces partnership with the American Society of Hematology to fight sickle cell disease in Sub-Saharan Africa. The partnership with ASH will not only deliver better tools to track a baby's diagnosis, but also support greater knowledge on treatment and care, including through publications on research findings, professional education and dissemination to policy makers and other audiences.

Medications Covered:

  • Stimulant
  • Non Stimulant
  • Other Medications

Psychotherapies Covered:

  • Behaviour Therapy
  • Cognitive Behavioural Therapy
  • Family Therapy
  • Interpersonal Psychotherapy
  • Other Psychotherapies

Education Or Trainings Covered:

  • Social Skills Training
  • Parent Management Training
  • School-Based Interventions
  • Other Education Or Trainings

Distribution Channels Covered:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Specialty Clinics
  • E-Commerce
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Attention Deficit Hyperactivity Disorder Market, By Medication

  • 5.1 Introduction
  • 5.2 Stimulant
    • 5.2.1 Amphetamine
    • 5.2.2 Dexmethylphenidate
    • 5.2.3 Methylphenidate
    • 5.2.4 Methylphenidate
    • 5.2.5 Lisdexamfetamine dimesylate
  • 5.3 Non Stimulant
    • 5.3.1 Atomoxetine
    • 5.3.2 Guanfacine
    • 5.3.3 Atomoxetine
    • 5.3.4 Clonidine
  • 5.4 Other Medications

6 Global Attention Deficit Hyperactivity Disorder Market, By Psychotherapy

  • 6.1 Introduction
  • 6.2 Behaviour Therapy
  • 6.3 Cognitive Behavioural Therapy
  • 6.4 Family Therapy
  • 6.5 Interpersonal Psychotherapy
  • 6.6 Other Psychotherapies

7 Global Attention Deficit Hyperactivity Disorder Market, By Education Or Training

  • 7.1 Introduction
  • 7.2 Social Skills Training
  • 7.3 Parent Management Training
  • 7.4 School-Based Interventions
  • 7.5 Other Education Or Trainings

8 Global Attention Deficit Hyperactivity Disorder Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Hospital Pharmacy
  • 8.4 Specialty Clinics
  • 8.5 E-Commerce
  • 8.6 Other Distribution Channel

9 Global Attention Deficit Hyperactivity Disorder Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Noven Pharmaceuticals, Inc.
  • 11.2 Takeda Pharmaceutical Company Limited
  • 11.3 Neos Therapeutics, Inc.
  • 11.4 Supernus Pharmaceuticals
  • 11.5 Novartis AG
  • 11.6 Johnson & Johnson
  • 11.7 Lilly, Pfizer Inc.
  • 11.8 Alcobra Ltd.
  • 11.9 Neurosigma, Inc
  • 11.10 Hisamitsu Pharmaceutical Co.,Inc
  • 11.11 KemPharm, Inc.
  • 11.12 Curemark, LLC.
  • 11.13 Mallinckrodt, UCB S.A.
  • 11.14 Purdue Pharma L.P.
  • 11.15 Actavis

List of Tables

  • Table 1 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
  • Table 3 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 4 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
  • Table 5 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
  • Table 6 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
  • Table 7 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 8 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 9 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
  • Table 10 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
  • Table 11 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 12 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
  • Table 13 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 14 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
  • Table 15 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
  • Table 16 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
  • Table 17 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 18 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
  • Table 19 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
  • Table 20 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
  • Table 21 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
  • Table 22 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
  • Table 23 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
  • Table 24 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 25 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
  • Table 26 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
  • Table 27 Global Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
  • Table 28 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
  • Table 29 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 30 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 31 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
  • Table 32 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
  • Table 33 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
  • Table 34 Global Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
  • Table 35 Global Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)
  • Table 36 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Country (2020-2028) ($MN)
  • Table 37 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
  • Table 38 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 39 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
  • Table 40 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
  • Table 41 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
  • Table 42 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 43 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 44 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
  • Table 45 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
  • Table 46 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 47 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
  • Table 48 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 49 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
  • Table 50 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
  • Table 51 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
  • Table 52 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 53 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
  • Table 54 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
  • Table 55 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
  • Table 56 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
  • Table 57 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
  • Table 58 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
  • Table 59 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 60 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
  • Table 61 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
  • Table 62 North America Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
  • Table 63 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
  • Table 64 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 65 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 66 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
  • Table 67 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
  • Table 68 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
  • Table 69 North America Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
  • Table 70 North America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)
  • Table 71 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Country (2020-2028) ($MN)
  • Table 72 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
  • Table 73 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 74 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
  • Table 75 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
  • Table 76 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
  • Table 77 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 78 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 79 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
  • Table 80 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
  • Table 81 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 82 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
  • Table 83 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 84 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
  • Table 85 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
  • Table 86 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
  • Table 87 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 88 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
  • Table 89 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
  • Table 90 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
  • Table 91 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
  • Table 92 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
  • Table 93 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
  • Table 94 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 95 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
  • Table 96 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
  • Table 97 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
  • Table 98 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
  • Table 99 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 100 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 101 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
  • Table 102 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
  • Table 103 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
  • Table 104 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
  • Table 105 Europe Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)
  • Table 106 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Country (2020-2028) ($MN)
  • Table 107 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
  • Table 108 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 109 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
  • Table 110 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
  • Table 111 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
  • Table 112 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 113 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 114 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
  • Table 115 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
  • Table 116 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 117 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
  • Table 118 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 119 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
  • Table 120 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
  • Table 121 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
  • Table 122 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 123 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
  • Table 124 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
  • Table 125 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
  • Table 126 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
  • Table 127 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
  • Table 128 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
  • Table 129 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 130 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
  • Table 131 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
  • Table 132 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
  • Table 133 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
  • Table 134 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 135 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 136 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
  • Table 137 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
  • Table 138 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
  • Table 139 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
  • Table 140 Asia Pacific Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)
  • Table 141 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Country (2020-2028) ($MN)
  • Table 142 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
  • Table 143 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 144 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
  • Table 145 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
  • Table 146 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
  • Table 147 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 148 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 149 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
  • Table 150 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
  • Table 151 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 152 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
  • Table 153 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 154 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
  • Table 155 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
  • Table 156 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
  • Table 157 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 158 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
  • Table 159 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
  • Table 160 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
  • Table 161 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
  • Table 162 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
  • Table 163 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
  • Table 164 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 165 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
  • Table 166 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
  • Table 167 South America Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
  • Table 168 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
  • Table 169 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 170 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 171 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
  • Table 172 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
  • Table 173 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
  • Table 174 South America Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
  • Table 175 South America Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)
  • Table 176 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Country (2020-2028) ($MN)
  • Table 177 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Medication (2020-2028) ($MN)
  • Table 178 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 179 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Stimulant (2020-2028) ($MN)
  • Table 180 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Amphetamine (2020-2028) ($MN)
  • Table 181 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Dexmethylphenidate (2020-2028) ($MN)
  • Table 182 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 183 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Methylphenidate (2020-2028) ($MN)
  • Table 184 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Lisdexamfetamine dimesylate (2020-2028) ($MN)
  • Table 185 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Non Stimulant (2020-2028) ($MN)
  • Table 186 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 187 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Guanfacine (2020-2028) ($MN)
  • Table 188 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Atomoxetine (2020-2028) ($MN)
  • Table 189 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Clonidine (2020-2028) ($MN)
  • Table 190 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Other Medications (2020-2028) ($MN)
  • Table 191 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Psychotherapy (2020-2028) ($MN)
  • Table 192 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 193 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Behaviour Therapy (2020-2028) ($MN)
  • Table 194 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Cognitive Behavioral Therapy (2020-2028) ($MN)
  • Table 195 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Family Therapy (2020-2028) ($MN)
  • Table 196 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Interpersonal Psychotherapy (2020-2028) ($MN)
  • Table 197 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Other Psychotherapies (2020-2028) ($MN)
  • Table 198 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Education Or Training (2020-2028) ($MN)
  • Table 199 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 200 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Social Skills Training (2020-2028) ($MN)
  • Table 201 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Parent Management Training (2020-2028) ($MN)
  • Table 202 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By School-Based Interventions (2020-2028) ($MN)
  • Table 203 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Other Education Or Trainings (2020-2028) ($MN)
  • Table 204 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 205 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Introduction (2020-2028) ($MN)
  • Table 206 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
  • Table 207 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
  • Table 208 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Specialty Clinics (2020-2028) ($MN)
  • Table 209 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By E-Commerce (2020-2028) ($MN)
  • Table 210 Middle East & Africa Attention Deficit Hyperactivity Disorder Market Outlook, By Other Distribution Channel (2020-2028) ($MN)